 NEW YORK, June 04, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Childrens Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma HR-NB patients in complete remission at the American Society of Clinical Oncology ASCO Virtual Annual Meeting on June 4, 2021 